Transgene (France) Top Management
TNG Stock | EUR 0.72 0.01 1.41% |
Transgene employs about 143 people. The company is managed by 10 executives with a total tenure of roughly 334 years, averaging almost 33.0 years of service per executive, having 14.3 employees per reported executive. Analysis of Transgene's management performance can provide insight into the company performance.
Maud MD Insider VP Officer |
Eric Quemeneur Insider Ex Officer |
Transgene |
Transgene Management Team Effectiveness
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Transgene Workforce Comparison
Transgene SA is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 693. Transgene totals roughly 143 in number of employees claiming about 21% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (1.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39. Transgene SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Transgene SA Price Series Summation is a cross summation of Transgene price series and its benchmark/peer.
Transgene Notable Stakeholders
A Transgene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Transgene often face trade-offs trying to please all of them. Transgene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Transgene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Maud MD | VP Officer | Profile | |
Eric Quemeneur | Ex Officer | Profile | |
Gaelle Stadtler | VP HR | Profile | |
JeanPhilippe Del | VP CFO | Profile | |
Hedi Brahim | CEO Director | Profile | |
Elisabetta Castelli | Director Relations | Profile | |
Lucie Larguier | Director IR | Profile | |
Steven RPh | VP Officer | Profile | |
LLM JD | Gen VP | Profile | |
Philippe Slos | Head Laboratory | Profile |
About Transgene Management Performance
The success or failure of an entity such as Transgene SA often depends on how effective the management is. Transgene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Transgene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Transgene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people.
Please note, the presentation of Transgene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Transgene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Transgene's management manipulating its earnings.
Transgene Workforce Analysis
Traditionally, organizations such as Transgene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Transgene within its industry.Transgene Manpower Efficiency
Return on Transgene Manpower
Revenue Per Employee | 69.9K | |
Revenue Per Executive | 999.3K | |
Net Loss Per Employee | 136.6K | |
Net Loss Per Executive | 2M | |
Working Capital Per Employee | 167.8K | |
Working Capital Per Executive | 2.4M |
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |